Lexicon Pharmaceuticals (LXRX) Reports Mixed Q4 Results
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.15 +6.97%
EPS Growth %: -600.0%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -600.0%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q4 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $343 thousand versus the consensus estimate of $290 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight
- Worried the AI trade has gone too far? Evercore likes these 4 stocks
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
